Who are Vedolizumab SC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tysabri, Anti-integrin - Vedolizumab IV, Vedolizumab IV, natalizumab (NTZ), BG00002 (natalizumab), Natalizumab (Tysabri).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vedolizumab-sc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vedolizumab SC — Competitive Intelligence Brief

Vedolizumab SC (Vedolizumab SC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrin antagonist; monoclonal antibody. Area: Immunology / Gastroenterology.

marketed Integrin antagonist; monoclonal antibody α4β7 integrin Immunology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Vedolizumab SC (Vedolizumab SC) — Takeda. Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vedolizumab SC TARGET	Vedolizumab SC	Takeda	marketed	Integrin antagonist; monoclonal antibody	α4β7 integrin
Tysabri	NATALIZUMAB	Biogen Idec	marketed	Integrin Receptor Antagonist [EPC]	α4β1 and α4β7 integrins	2004-01-01
Anti-integrin - Vedolizumab IV	Anti-integrin - Vedolizumab IV	University of Calgary	marketed	Anti-integrin monoclonal antibody	α4β7 integrin
Vedolizumab IV	Vedolizumab IV	Takeda	marketed	Integrin antagonist monoclonal antibody	α4β7 integrin
natalizumab (NTZ)	natalizumab (NTZ)	University Hospital, Clermont-Ferrand	marketed	Monoclonal antibody (integrin antagonist)	α4β1 integrin (VLA-4)
BG00002 (natalizumab)	BG00002 (natalizumab)	Biogen	marketed	Monoclonal antibody (integrin antagonist)	α4β1 integrin
Natalizumab (Tysabri)	Natalizumab (Tysabri)	Cornerstone Health Care, PA	marketed	Monoclonal antibody; integrin antagonist	α4β1 integrin (VLA-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrin antagonist; monoclonal antibody class)

Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vedolizumab SC — Competitive Intelligence Brief. https://druglandscape.com/ci/vedolizumab-sc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab